Baker Ellis Asset Management LLC Has $250,000 Stake in Quest Diagnostics Incorporated (NYSE:DGX)
Baker Ellis Asset Management LLC continued to hold its position in Quest Diagnostics Incorporated (NYSE:DGX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,250 shares of the medical research company’s stock at the end of the second quarter. Baker Ellis Asset Management LLC’s holdings in Quest Diagnostics were worth $250,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of the stock. YorkBridge Wealth Partners LLC increased its position in Quest Diagnostics by 1.5% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,188 shares of the medical research company’s stock valued at $127,000 after buying an additional 18 shares during the last quarter. Parallel Advisors LLC increased its position in Quest Diagnostics by 16.1% in the first quarter. Parallel Advisors LLC now owns 1,279 shares of the medical research company’s stock valued at $137,000 after buying an additional 177 shares during the last quarter. Advisors Capital Management LLC bought a new position in Quest Diagnostics during the first quarter valued at about $164,000. Trust Co. of Vermont increased its position in Quest Diagnostics by 8.5% in the first quarter. Trust Co. of Vermont now owns 1,859 shares of the medical research company’s stock valued at $182,000 after buying an additional 145 shares during the last quarter. Finally, Financial Architects Inc increased its position in Quest Diagnostics by 5.6% in the second quarter. Financial Architects Inc now owns 1,666 shares of the medical research company’s stock valued at $185,000 after buying an additional 88 shares during the last quarter. 90.97% of the stock is currently owned by institutional investors and hedge funds.
Shares of Quest Diagnostics Incorporated (NYSE:DGX) opened at 106.73 on Tuesday. The company’s 50-day moving average is $109.18 and its 200 day moving average is $102.41. The firm has a market capitalization of $14.56 billion, a PE ratio of 21.51 and a beta of 0.69. Quest Diagnostics Incorporated has a 52-week low of $79.12 and a 52-week high of $112.96.
Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.42 by $0.13. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 EPS. Equities analysts expect that Quest Diagnostics Incorporated will post $5.69 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, July 24th. Stockholders of record on Monday, July 10th were paid a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.69%. The ex-dividend date was Thursday, July 6th. Quest Diagnostics’s dividend payout ratio is currently 36.29%.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/08/baker-ellis-asset-management-llc-has-250000-stake-in-quest-diagnostics-incorporated-nysedgx.html.
DGX has been the topic of several recent analyst reports. Mizuho reaffirmed a “buy” rating and set a $90.00 price objective (down from $103.00) on shares of Quest Diagnostics in a report on Friday, April 14th. Deutsche Bank AG reaffirmed a “buy” rating and set a $115.00 price objective (up from $108.00) on shares of Quest Diagnostics in a report on Sunday, April 23rd. Canaccord Genuity increased their price objective on shares of Quest Diagnostics from $102.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, April 25th. UBS AG reaffirmed a “buy” rating and set a $115.00 price objective (up from $102.00) on shares of Quest Diagnostics in a report on Tuesday, April 25th. Finally, Zacks Investment Research raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $119.00 price objective on the stock in a report on Tuesday, May 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $110.72.
In other news, SVP Catherine T. Doherty sold 59,762 shares of the company’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $107.55, for a total transaction of $6,427,403.10. Following the completion of the transaction, the senior vice president now owns 78,582 shares of the company’s stock, valued at approximately $8,451,494.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey M. Leiden sold 1,304 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $108.73, for a total transaction of $141,783.92. Following the transaction, the director now directly owns 6,296 shares of the company’s stock, valued at approximately $684,564.08. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.